Cargando…

Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results

BACKGROUND: We designed a new surgical procedure to treat benign prostatic hyperplasia(BPH). In order to verify its effectiveness and safety, we constructed this randomized controlled trial to compare the efficacy of our innovative enucleation technique- photoselective sharp enucleation of the prost...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhengchao, Chen, Zhipeng, Yan, Dishi, Jiang, Tao, Fu, Jian, Zheng, Jun, Zhou, Yuanxiu, Zhou, Zhansong, Shen, Wenhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639323/
https://www.ncbi.nlm.nih.gov/pubmed/36344969
http://dx.doi.org/10.1186/s12894-022-01129-x
_version_ 1784825613117292544
author Liu, Zhengchao
Chen, Zhipeng
Yan, Dishi
Jiang, Tao
Fu, Jian
Zheng, Jun
Zhou, Yuanxiu
Zhou, Zhansong
Shen, Wenhao
author_facet Liu, Zhengchao
Chen, Zhipeng
Yan, Dishi
Jiang, Tao
Fu, Jian
Zheng, Jun
Zhou, Yuanxiu
Zhou, Zhansong
Shen, Wenhao
author_sort Liu, Zhengchao
collection PubMed
description BACKGROUND: We designed a new surgical procedure to treat benign prostatic hyperplasia(BPH). In order to verify its effectiveness and safety, we constructed this randomized controlled trial to compare the efficacy of our innovative enucleation technique- photoselective sharp enucleation of the prostate (PSEP), with a front-firing 532-nm laser and the traditional technique-photoselective vaporization of the prostate (PVP) in the treatment of BPH. METHODS: A total of 154 consecutive patients diagnosed with bladder outlet obstruction secondary to BPH in our center from June 2018 to April 2019 were randomly divided into the PSEP group (n = 77) and the PVP group (n = 77) and were treated surgically with either PSEP or PVP. All patients were assessed preoperatively and followed up at 1, 6, and 12 months postoperatively. The international prostate symptom score,quality-of-life score, postvoid residual urine volume, maximum urine flow rate, prostate volume, prostate-specific antigen, and adverse events were compared. RESULTS: The lower urinary tract symptoms in both groups were significantly improved compared with the baseline at 1, 6, and 12 months postoperatively. The PSEP and PVP groups had an equivalent International Prostate Symptom Score, quality-of-life score, postvoid residual urine volume, maximum urine flow rate, prostate-specific antigen at each follow-up (P > 0.05). The median operative time in the PSEP group was significantly shorter than that in the PVP group (35 min vs. 47 min, P < 0.001). At 6 and 12 months after surgery, the median PV in the PSEP group was smaller than that in the PVP group (P < 0.05). Complication rates were comparable between the groups. CONCLUSION: Both PSEP and PVP can achieve good efficacy and safety in the treatment of BPH. PSEP can remove more tissue than PVP and is associated with higher efficiency. In addition, PSEP eliminates the problem of lack of tissue samples associated with PVP. TRIAL REGISTRATION: Chinese Clinical Trial Registry, identifie:ChiCTR1800015867, date:25/04/2018.
format Online
Article
Text
id pubmed-9639323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96393232022-11-08 Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results Liu, Zhengchao Chen, Zhipeng Yan, Dishi Jiang, Tao Fu, Jian Zheng, Jun Zhou, Yuanxiu Zhou, Zhansong Shen, Wenhao BMC Urol Research BACKGROUND: We designed a new surgical procedure to treat benign prostatic hyperplasia(BPH). In order to verify its effectiveness and safety, we constructed this randomized controlled trial to compare the efficacy of our innovative enucleation technique- photoselective sharp enucleation of the prostate (PSEP), with a front-firing 532-nm laser and the traditional technique-photoselective vaporization of the prostate (PVP) in the treatment of BPH. METHODS: A total of 154 consecutive patients diagnosed with bladder outlet obstruction secondary to BPH in our center from June 2018 to April 2019 were randomly divided into the PSEP group (n = 77) and the PVP group (n = 77) and were treated surgically with either PSEP or PVP. All patients were assessed preoperatively and followed up at 1, 6, and 12 months postoperatively. The international prostate symptom score,quality-of-life score, postvoid residual urine volume, maximum urine flow rate, prostate volume, prostate-specific antigen, and adverse events were compared. RESULTS: The lower urinary tract symptoms in both groups were significantly improved compared with the baseline at 1, 6, and 12 months postoperatively. The PSEP and PVP groups had an equivalent International Prostate Symptom Score, quality-of-life score, postvoid residual urine volume, maximum urine flow rate, prostate-specific antigen at each follow-up (P > 0.05). The median operative time in the PSEP group was significantly shorter than that in the PVP group (35 min vs. 47 min, P < 0.001). At 6 and 12 months after surgery, the median PV in the PSEP group was smaller than that in the PVP group (P < 0.05). Complication rates were comparable between the groups. CONCLUSION: Both PSEP and PVP can achieve good efficacy and safety in the treatment of BPH. PSEP can remove more tissue than PVP and is associated with higher efficiency. In addition, PSEP eliminates the problem of lack of tissue samples associated with PVP. TRIAL REGISTRATION: Chinese Clinical Trial Registry, identifie:ChiCTR1800015867, date:25/04/2018. BioMed Central 2022-11-07 /pmc/articles/PMC9639323/ /pubmed/36344969 http://dx.doi.org/10.1186/s12894-022-01129-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Zhengchao
Chen, Zhipeng
Yan, Dishi
Jiang, Tao
Fu, Jian
Zheng, Jun
Zhou, Yuanxiu
Zhou, Zhansong
Shen, Wenhao
Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title_full Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title_fullStr Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title_full_unstemmed Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title_short Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
title_sort photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639323/
https://www.ncbi.nlm.nih.gov/pubmed/36344969
http://dx.doi.org/10.1186/s12894-022-01129-x
work_keys_str_mv AT liuzhengchao photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT chenzhipeng photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT yandishi photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT jiangtao photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT fujian photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT zhengjun photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT zhouyuanxiu photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT zhouzhansong photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults
AT shenwenhao photoselectivesharpenucleationoftheprostatewithafrontfiring532nmlaserversusphotoselectivevaporizationoftheprostateinthetreatmentofbenignprostatichyperplasiaarandomisedcontrolledtrialwith1yearfollowupresults